Case report
A case of syringotropic cutaneous T-cell lymphoma treated with local radiotherapy

https://doi.org/10.1016/j.jaad.2008.05.042Get rights and content

Syringotropic cutaneous T-cell lymphoma (SCTCL) is a variant of mycosis fungoides that is characterized by the presence of lymphocytic infiltration of eccrine glandular structures and the absence of the classic features of MF, such as epidermotropism and Pautrier's microabscesses. We report a patient with SCTCL who presented with multiple hypopigmented patches and localized alopecia who was treated with local radiotherapy with excellent local control. In our experience, local electron radiation offers local control in early stage SCTCL, and it may be possible to reserve systemic therapy for more advanced stages of the disease.

Section snippets

Discussion

Patients with SCTCL characteristically present with punctuate erythematous or hypopigmented plaques. Alopecia, hypoesthesia, and anhydrosis are variably associated with this condition.1, 2 Occasionally, SCTCL presents with erythroderma, skin nodules or lymphadenopathy mimicking scleroderma, or Sézary syndrome.3, 4 It is reported that SCTCL could occur at sites of actinic exposure, theorizing that the relative depletion of Langerhan cells caused by sun damage could curtail immune surveillance

Conclusion

Our experience confirms the excellent outcome in early stage SCTCL with local radiotherapy. While it is difficult to make broad therapeutic recommendations based on a single case report, we believe that it may be possible to reserve systemic therapy for more advanced stages of the disease. In addition to irradiating early lesions, we recommend close follow-up after treatment with periodic skin checks and early intervention if required.

References (10)

There are more references available in the full text version of this article.

Cited by (11)

  • Syringotropic cutaneous T-cell lymphoma mimicking dermatomycosis

    2012, Annales de Dermatologie et de Venereologie
View all citing articles on Scopus

Funding sources: None.

Conflicts of interest: None declared.

View full text